Acromegaly
Mostrando 1-12 de 105 artigos, teses e dissertações.
-
1. Impact of the COVID-19 pandemic in the treatment of patients with acromegaly in a tertiary center: a wake-up call on the importance of telemedicine
ABSTRACT Objective: The COVID-19 pandemic has profoundly disrupted health care worldwide. We aimed to evaluate the impact of the first COVID-19 wave on the treatment of our patients with acromegaly. Subjects and methods: A standard questionnaire was systematically applied to all patients and included questions on general health status, whether all laborato
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
2. Patient's point of view on the diagnosis, treatment, and follow-up in acromegaly: single-center study from a tertiary center
SUMMARY OBJECTIVE: We aimed to evaluate the awareness and perspectives of acromegaly patients in the diagnosis and treatment processes and to evaluate basic clinical and demographic features. METHODS: This cross-sectional study was conducted at the Endocrinology Department of Yildirim Beyazit University between March 2019 and April 2020. A total of 58 acro
Revista da Associação Médica Brasileira. Publicado em: 2022
-
3. Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature
ABSTRACT Objective: It is reported that adding cabergoline to somatostatin analog (SSA) normalizes IGF-1 levels approximately in one-third of patients with acromegaly. We investigated the effect of combination therapy and potential predictors of response in patients with acromegaly who do not respond to SSA therapy alone. Subjects and methods: Fifty acrome
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
4. Dopaminergic treatment of patients with acromegaly: still kicking after all these years
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
5. Can telemedicine improve adherence to medical treatment? Lessons learned from research on acromegaly conducted during COVID-19 pandemic
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
6. Erratum: Impact of the COVID-19 pandemic in the treatment of patients with acromegaly in a tertiary center: a wake-up call on the importance of telemedicine
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
7. Comparison between somatostatin analog injections
SUMMARY OBJECTIVE: Long-acting depot formulations of somatostatin analogs, i.e., octreotide and lanreotide, are the first-line medical therapies for patients with acromegaly to whom surgery/radiotherapy cannot be performed or who have inadequate response. In this study, we aimed to evaluate the short-term local and systemic adverse reactions developed after
Revista da Associação Médica Brasileira. Publicado em: 2022
-
8. The state of Sergipe contribution to GH research: from Souza Leite to Itabaianinha syndrome
ABSTRACT In the late 19th century, José Dantas de Souza Leite, a physician born in Sergipe, published the first detailed clinical description of acromegaly under the guidance of the French neurologist Pierre Marie. In 2014, the Brazilian Society of Endocrinology and Metabolism created the “José Dantas de Souza Leite Award”, which is granted every two y
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
9. A novel mutation in PRKAR1A gene in a patient with Carney complex presenting with pituitary macroadenoma, acromegaly, Cushing's syndrome and recurrent atrial myxoma
SUMMARY Carney complex (CNC) is a rare syndrome of multiple endocrine and non-endocrine tumors. In this paper we present a 23-year-old Iranian woman with CNC who harbored a novel mutation (c.642dupT) in PRKAR1A gene. This patient presented with pituitary macroadenoma, acromegaly, recurrent atrial myxoma, Cushing's syndrome secondary to primary pigmented nodu
Arch. Endocrinol. Metab.. Publicado em: 2021-06
-
10. Thyroid gland changes in patients with acromegaly
ABSTRACT Objective Acromegaly is characterized by high neoplastic morbidity as a side effect of growth hormone (GH) hypersecretion. Increased incidence of goiter, thyroid carcinoma, and thyroid dysfunction is also reported. The aim of the present study was to find the prevalence of thyroid dysfunction and goiter in patients with acromegaly and determine it
Arch. Endocrinol. Metab.. Publicado em: 2020-06
-
11. Determinants of morbidities and mortality in acromegaly
ABSTRACT Acromegaly is a systemic disease associated with increased morbidity, presenting cardiovascular, metabolic, respiratory, neoplastic, endocrine, articular and bone complications. Most of these comorbidities can be prevented or delayed with adequate disease treatment and, more recent studies with the use of modern treatments of acromegaly, have shown
Arch. Endocrinol. Metab.. Publicado em: 10/01/2020
-
12. Acromegaly in the elderly patient
ABSTRACT Acromegaly is an insidious disease, usually resulting from growth hormone hypersecretion by a pituitary adenoma. It is most often diagnosed during the 3rd to 4th decade of life. However, recent studies have shown an increase in the incidence and prevalence of acromegaly in the elderly, probably due to increasing life expectancy. As in the younger po
Arch. Endocrinol. Metab.. Publicado em: 10/01/2020